1. Introduction {#sec1}
===============

Recently the nonmotor symptoms (NMS) of Parkinson\'s disease (PD) have been increasingly recognized as major burden of quality of life \[[@B1], [@B2]\]. The recently published Movement Disorder Society-sponsored Unified Parkinson\'s Disease Rating Scale (MDS-UPDRS) was developed to assess a wide variety of nonmotor symptoms with good scale properties. However, there are only a few published studies available contrasting the MDS-UPDRS to other validated scales on NMS. One of the papers demonstrated that the MDS-UPDRS Part I for nonmotor experiences of daily living had a strong convergent validity to the Non-Motor Symptoms Questionnaire with the exception of patients with the most severe NMS \[[@B1]\]. However, the NMS Questionnaire is a general scale and not an instrument specially designed for certain aspects of PD. In another recently published paper, the individual items of MDS-UPDRS Part I were validated against a number of scales for assessing individual NMS. However, this study included a relatively low number of patients (*n* = 94) and utilized the sole means of correlation calculations \[[@B3]\]. Although this research confirmed that the MDS-UPDRS Part I total score had a strong convergent validity with a composite score of scales for the NMS of PD and the majority of items of MDS-UPDRS Part I had at least moderate correlation with the representative nonmotor scales, the methodology applied was unable to confirm agreement and concordance. In our opinion, Spearman\'s correlation coefficient is an inappropriate measure of reliability because the strength of linear association, and not agreement, is measured. Therefore, it is possible to have a high degree of correlation even if agreement is poor \[[@B4], [@B5]\]. Because one of the most important questions in assessing the model validity is if the model-predicted values are precise and accurate at the same time \[[@B6]\], concordance correlation measurements should be utilized to establish agreement (concordance) by two scales.

Sleep-related problems are one of the most important and troublesome nonmotor aspects of PD. These problems are certainly multidimensional. For example, sleep-disturbances associated with PD might be equally due to troublesome nighttime OFF symptoms and other issues not specific for PD (e.g., microarousals caused by sleep apnea syndrome). Similarly, daytime sleepiness in PD might also be caused by PD-specific or nonspecific causes.

MDS-UPDRS has separate items for measuring nighttime sleep-related problems (item 1.7) and daytime sleepiness (1.8) each ranging from 0 (not present) to 4 (severe) scores. The aim of our study was to evaluate the relationship of these items to the PD Sleep Scale 2nd version (PDSS-2) and the Epworth Sleepiness Scale (ESS).

The Parkinson\'s Disease Sleep Scale 2nd version is a validated scale to assess sleep problems in PD \[[@B7]\]. It is composed of 15 items evaluating three domains. Each item has a 5-point Likert-type scale ranging from 0 "never" to 4 "very often" (except for item 1 which is reversed). Each domain consists of clusters of five questions (motor symptoms at night: 4, 5, 6, 12, and 13; PD symptoms at night: 7, 9--11, and 15; and disturbed sleep: 1--3, 8, and 14) \[[@B7]\]. Symptoms on each domain can be scored in the range of 0--20 points, higher scores meaning more nocturnal disturbance. The sum of the three domains gives the total score of PDSS-2 with the maximum value of 60 points. The threshold indicating sleep problems is 11 points for the Hungarian version of PDSS-2 \[[@B8]--[@B10]\].

Epworth Sleepiness Scale is composed of 8 items investigating a single domain to assess daytime sleepiness. The usefulness of ESS was demonstrated in PD by several studies \[[@B11]--[@B14]\]. Each item is scaled from 0 "would never doze" to 3 "high chance to doze." The total score of ESS is the sum of all item scores (0--24 points), higher scores representing more severe daytime sleepiness. The cutoff value indicating daytime sleepiness in Hungarian PD patients is 5 points \[[@B8]\].

2. Materials and Methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

In this nationwide cross-sectional multicenter study 460 patients fulfilling the UK Brain Bank criteria for PD were enrolled. Each subject gave written consent in accordance with the ethical approval of the National Ethical Committee (184/2013. 14437/2013/EKU). Each patient was examined by a neurologist specialized in movement disorders. A portion of these patients (357/460) participated in the program of cultural adaptation and validation of the MDS-UPDRS into Hungarian. Data were summarized at University of Pécs (by KH and NK). Subsequently, levodopa equivalent dosage calculations were performed \[[@B15]\].

Patients were screened for the presence of dementia by the means of the Hungarian validated versions of Mattis Dementia Rating Scale \[[@B16]\] (MDRS, *n* = 345 patients) and the Montreal Cognitive Assessment \[[@B17]\] (MOCA, *n* = 460 patients). Patients receiving scores ≤125 points on Mattis test and/or scores ≤22 points on MOCA were considered as having major neurocognitive disorders \[[@B16]\].

2.2. Obtained Rating Scales {#sec2.2}
---------------------------

Besides sociodemographic and PD-historic data, the Hungarian validated versions of MDS-UPDRS \[[@B18]\], PDSS-2 \[[@B8]\], and ESS \[[@B8], [@B19]\] were obtained. Because data from these scales were categorical, nonparametric tests were applied. As being part of the MDS-UPDRS, Hoehn-Yahr Scale was also used to detect the overall severity of PD. For description, medians with interquartile range (IR, 25th--75th percentiles) were calculated.

2.3. Prevalence and Correlations {#sec2.3}
--------------------------------

Because the score of 0 on the items means symptom-free condition, the prevalence of each item was based on the portion of subjects having the score \>0 point on that particular item.

For correlation, Spearman\'s rank correlation coefficients were calculated. For correlation coefficients, the values 0--0.299 were indicative of weak correlation, 0.300--0.599 were indicative of moderate correlation, and 0.600--1.000 were considered as high association \[[@B20]\].

2.4. Regression Models and Lin\'s Concordance Correlation {#sec2.4}
---------------------------------------------------------

To evaluate the relationship between the scales, models of generalized ordinal logistic regression were built with bootstrap replication. Because most regression algorithms are very sample specific, their generalizability to other samples is quite limited. We chose a generalized logistic regression model with lasso regularization as this method allowed for bootstrap cross validation. Using this option we could generalize the results to samples outside the index sample.

To determine the relationship between the PDSS-2 and the "sleep problems" item of MDS-UPDRS (1.7), generalized ordinal logistic regression was applied. First, we converted the PDSS-2 scores to MDS-UPDRS item 1.7 by regression analysis. Subsequently, Lin\'s Concordance Correlation Coefficient (LCCC) \[[@B21]\] was used to calculate the concordance between the true MDS-UPDRS scores and those estimated from the PDSS-2. The concordance was categorized by the value of LCCC as acceptable (0.601--0.900) and good (0.901--1.000).

Similar approach was utilized to determine the relationship between ESS and "daytime sleepiness" item of MDS-UPDRS (1.8). Based on the obtained generalized ordinal logistic regression model we converted the ESS scores to MDS-UPDRS item 1.8 and subsequently LCCC were calculated between the true and estimated MDS-UPDRS 1.8 values.

2.5. Receiver Operating Characteristic (ROC) Curve {#sec2.5}
--------------------------------------------------

In order to analyze how efficiently the MDS-UPDRS differentiates patients having sleep-related problems from those who do not have any sleep-related problems, we applied ROC analysis. After categorization of patients into two groups based on their total score on PDDS-2 (patients with sleep problems: total PDSS-2 score ≥11 points and patients without sleep problems: \<11 points), we performed a second categorization based on MDS-UPDRS item 1.7 score (patients with sleep problems: \>0 points, patients without sleep problems: 0 points). Subsequently these two different categorization methods were compared to obtain positive and negative predictive values, specificity, and sensitivity.

Afterwards, we also evaluated how appropriately the MDS-UPDRS 1.8 item identified patients with daytime sleepiness. Categorization based on the ESS scores (patients having daytime sleepiness: total score ≥5 points versus those not having daytime sleepiness, ESS \<5 points) was compared to that of MDS-UPDRS item 1.8.

2.6. Statistical Analysis {#sec2.6}
-------------------------

All statistical analyses were carried out using IBM SPSS software package (version 21, SPSS Inc., Chicago, USA). Statistical significance level was set to 5%. Because the SPSS Suite did not have built-in functions for calculating LCCC, the freely available syntax files developed by Marta Garcia-Granero were utilized (available: http://gjyp.nl/marta/, accessed at Jan 7, 2013). Positive and negative predictive values were calculated by the utilization of the syntax adapted from the IBM website (<http://www-01.ibm.com/support/docview.wss?uid=swg21483380>).

3. Results {#sec3}
==========

3.1. Demographic and PD-Related Clinical Data {#sec3.1}
---------------------------------------------

The subject population consisted of 460 PD patients. The clinical characteristics are demonstrated in [Table 1](#tab1){ref-type="table"}. The LED was 214 mg (14--324 mg, median and 25th--75th percentiles).

3.2. Sleep Problems {#sec3.2}
-------------------

Based on MDS-UPDRS item 1.7, 315 patients (68.4%) had sleep-related problems (prevalence, score \>0). Only 1.7% of patients had the total score of 0 on PDSS-2. According to the PDSS total score, 324 patients (70.4%) had sleep-related problems clinically (score ≥11 points). Item 8 had the highest prevalence on PDSS-2 (nocturia: 91.0%), while the lowest was at item 7 (hallucinations: 15.0%). Out of the three domains of PDSS-2, the "disturbed sleep" had the highest prevalence (98.3%). Prevalence, frequency, and median values of sleep-related items are demonstrated in [Table 2](#tab2){ref-type="table"}.

Eight items of PDSS-2 had poor correlation with the "sleep problems" item of MDS-UPDRS (6: distressing dreams at night, 7: nighttime distressing hallucinations, 8: nocturia, 9: immobility at night, 11: nighttime muscle cramps in extremities, 12: painful posturing in the morning, 13: tremor, and 15: snoring or difficulties in breathing). Six items had moderate correlation with item 1.7 of MDS-UPDRS (1: bad sleep quality, 2: difficulties falling asleep, 4: restlessness of extremities at night, 5: urge to move extremities, 10: pain in extremities, and 14: tired and sleepy after waking in the morning). Furthermore, the total score and two domains of PDSS-2 (motor symptoms and PD symptoms at night) had also moderate correlation coefficients. Only a single item (3: difficulties staying asleep) and the "disturbed sleep" domain of PDSS-2 had high correlation with the "sleep problems" item of MDS-UPDRS ([Table 2](#tab2){ref-type="table"}).

Generalized ordinal logistic regression model was developed for PDSS-2 items to estimate MDS-UPDRS item 1.7. Only PDSS items 1, 2, 3, and 5 contributed significantly to the model (Supplementary Table 1 in Supplementary Materials available online at <http://dx.doi.org/10.1155/2014/806169>). The details of the ordinal logistic regression model are presented in Supplementary Table 2. The predicted MDS-UPDRS 1.7 values were subsequently compared to the true MDS-UPDRS 1.7 values by LCCC. The value of LCCC was 0.833 (95% confidence interval: 0.809--0.864) demonstrating acceptable agreement between the PDSS-2 and the "sleep problems" item of MDS-UPDRS.

Based on the ROC analysis, MDS-UPDRS item 1.7 can differentiate between patients with and without sleep-related problems measured by PDSS-2 reliably (positive predictive value: 0.714 with the 95% CI of 0.633--0.794; negative predictive value: 0.851 with the 95% CI of 0.809--0.887; sensitivity: 0.754 with the 95% CI of 0.672--0.831; and specificity: 0.827 with 95% CI: 0.783--0.866).

3.3. Daytime Sleepiness {#sec3.3}
-----------------------

Based on MDS-UPDRS item 1.8, 345 patients (75.0%) had problems with daytime sleepiness (prevalence, score \>0). Only 4.74% of patients had the total score of 0 points on ESS. According to ESS total score, 312 patients (67.8%) clinically had daytime sleepiness (ESS score ≥5 points). None of the items of ESS showed high correlation with MDS-UPDRS item 1.8. While items 1--4 had moderate correlation, items 5--8 had only poor correlation. The highest value of correlation coefficient was observed between the total score of ESS and item 1.8 of MDS-UPDRS (0.494) ([Table 3](#tab3){ref-type="table"}).

Generalized ordinal logistic regression model was developed for ESS items to estimate MDS-UPDRS item 1.8. Only ESS items 1, 2, 3, and 7 contributed significantly to the model (Supplementary Table 3). The details of the ordinal logistic regression model are presented in Supplementary Table 4. The predicted MDS-UPDRS 1.8 values were subsequently compared to the true MDS-UPDRS 1.8 values by LCCC. The value of LCCC was 0.638 (95% confidence interval: 0.561--0.708) demonstrating acceptable agreement between ESS and "daytime sleepiness" item of MDS-UPDRS.

Based on the ROC analysis, MDS-UPDRS item 1.8 can differentiate between patients with and without daytime sleepiness measured by ESS reliably (positive predictive value: 0.617 with the 95% CI of 0.527--0.703; negative predictive value: 0.777 with the 95% CI of 0.731--0.819; sensitivity: 0.580 with the 95% CI of 0.500--0.660; and specificity: 0.859 with 95% CI: 0.817--0.895).

4. Discussion {#sec4}
=============

Our data supports that the PDSS-2 has a strong and convergent validity to "sleep problems" item of MDS-UPDRS. Several items of disturbed sleep domain (items 1--3) had the best correlation with MDS-UPDRS item 1.7. This relationship is not surprising, because the question of item 1.7 queries the following: "Over the past week, have you had trouble going to sleep at night or staying asleep through the night? Consider how rested you felt after waking up in the morning." The possible answers in MDS-UPDRS emphasize the length of staying asleep (1: easily able to get a full night sleep, 2: with difficulties can achieve a full night sleep, 3: stay asleep more than the half the night, and 4: less than half of the night). The most concordant item (number 3) of PDSS-2 asks also about difficulty staying asleep, and the other acceptably concordant questions (1: bad sleep quality and 2: difficulties falling asleep) also contribute to this "disturbed sleep" domain.

For daytime sleepiness, we found considerably smaller correlation between the ESS and MDS-UPDRS item 1.8 than Gallagher and coworkers did \[[@B3]\]. In their paper Spearman\'s correlation coefficient was 0.56 based on the sample of 94 patients while our 0.494 value was based on the analysis of 460 patients. The discrepancy might be due to the differences in the sample size and other patient characteristics. We might assume at least two reasons behind these low correlation coefficients: MDS-UPDRS and ESS apply different time-frame and severity measurements. Whereas ESS asks the patient to base his/her answer referring to "recent times," the MDS-UPDRS assesses the usual function "over the past week including today." ESS evaluates how likely the patient will doze off in different situations (e.g., sitting and reading, being a passenger in a car, and sitting and talking to someone else). This type of severity scale assesses the frequency and likelihood to differentiate between scores 1--3. On the contrary, the severity scale of MDS-UPDRS item 1.8 is based not only on the frequency (e.g., 3: sometimes versus 4: often), but also on the different types of conditions where the patient would fall asleep (e.g., 2: being alone and relaxing; 3-4: eating or talking to people). Despite these concerns, we found acceptable agreement between the ESS items and the daytime sleepiness item of MDS-UPDRS.

The authors are aware of some limitations of the study. Despite having a relatively large sample of patients, the majority of the subjects had mild to moderate disease severity (Hoehn-Yahr Scale: 1--3). To overcome this problem, we utilized a generalized logistic regression model with lasso regularization as this method allowed for bootstrap cross validation. Using this option we could generalize the results to samples outside the index sample.

5. Conclusions {#sec5}
==============

Our data demonstrate that the MDS-UPDRS nonmotor experiences of daily works as a good screening questionnaire aimed at identifying areas of disability related to sleep problems and daytime sleepiness. The scale itself registers presence and severity of items but has an official APPENDIX with recommended more specific scales to pursue areas in more detail. As a screening tool, there are some aspects of sleep and daytime sleepiness which are not covered by MDS-UPDRS, but the presence of nonzero scores on these MDS-UPDRS items allows for fruitful utilization of more specific and detailed rating instruments. In our view, studies focusing on the sleep-related problems in PD can begin with the MDS-UPDRS to accurately identify the cohort with sleep problems, and then this group can be studied with the PDDS-2 and ESS serving to assess all major dimensions in greater detail.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplementary data: This files detailed information on the developedgeneralized ordinal logistic models.
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###### 

Clinical characteristics of the study cohort.

  Characteristics                                      Mean/number   Percentage
  ---------------------------------------------------- ------------- ------------
  Age                                                  65.6 ± 9.7     
  Disease-duration                                     8.3 ± 7.8      
  Education years                                      11.8 ± 3.2     
  Sex                                                  293 males     63.7%
  Fluctuation                                          236           51.3%
  Dyskinesia                                           184           40.0%
  Hoehn-Yahr stage I                                   31            6.7%
  Hoehn-Yahr stage II                                  275           59.8%
  Hoehn-Yahr stage III                                 115           25.0%
  Hoehn-Yahr stage IV                                  28            6.1%
  Hoehn-Yahr stage V                                   11            2.4%
  Deep brain stimulation therapy                       113           24.5%
  Levodopa/carbidopa intestinal gel infusion therapy   10            2.2%
  Levodopa                                             358           77.8%
  Dopamine agonists                                    299           65.0%
  Without medication                                   14            3.0%
  Levodopa and dopamine agonist combination            118           25.7%
  COMT-inhibition                                      208           45.2%
  MAO-inhibition                                       108           23.5%
  Anticholinergic therapy                              10            2.2%
  Presence of dementia                                 **10**        **2.2%**
  Antipsychotic medication                             **8**         **1.74%**
  Sedative medication usage                            **25**        **5.43%**

Presence of dementia was defined as having scores ≤125 points on Mattis Dementia Rating Scale and/or scores ≤22 points on Montreal Cognitive Assessment.

###### 

Prevalence, frequency, and correlation values for sleep-related problems.

                                Prevalence   Frequency of score 0   Frequency of score 1   Frequency of score 2   Frequency of score 3   Frequency of score 4   Median   Percentile 25   Percentile 75   Correlation with MDS-UPDRS item 1.7
  ----------------------------- ------------ ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- -------- --------------- --------------- -------------------------------------
  MDS-UPDRS item 1.7            68.5%        145                    100                    82                     108                    25                     1        0               3               1.000
                                                                                                                                                                                                         
  PDSS item number 01           68.0%        147                    125                    99                     58                     31                     1        0               2               .573^\*\*^
  PDSS item number 02           50.9%        226                    79                     91                     44                     20                     1        0               2               .546^\*\*^
  PDSS item number 03           67.4%        150                    87                     81                     73                     69                     1        0               3               .682^\*\*^
  PDSS item number 04           52.2%        220                    74                     86                     53                     27                     1        0               2               .369^\*\*^
  PDSS item number 05           51.1%        225                    80                     80                     48                     27                     1        0               2               .390^\*\*^
  PDSS item number 06           43.0%        262                    91                     79                     18                     10                     0        0               1               .156^\*\*^
  PDSS item number 07           15.0%        391                    40                     19                     5                      5                      0        0               0               .169^\*\*^
  PDSS item number 08           91.1%        41                     97                     102                    109                    111                    2        1               3               .275^\*\*^
  PDSS item number 09           48.7%        236                    61                     64                     62                     37                     0        0               2               .238^\*\*^
  PDSS item number 10           51.3%        224                    74                     86                     50                     26                     1        0               2               .323^\*\*^
  PDSS item number 11           57.2%        197                    101                    94                     45                     23                     1        0               2               .283^\*\*^
  PDSS item number 12           42.8%        263                    68                     62                     45                     22                     0        0               2               .268^\*\*^
  PDSS item number 13           45.7%        250                    64                     60                     54                     32                     0        0               2               .127^\*\*^
  PDSS item number 14           70.9%        134                    135                    102                    56                     33                     1        0               2               .302^\*\*^
  PDSS item number 15           31.7%        314                    65                     56                     15                     10                     0        0               1               .189^\*\*^
                                                                                                                                                                                                         
  PDSS motor domain             82.7%                                                                                                                           4        2               7               .398^\*\*^
  PDSS PD symptoms domain       82.3%                                                                                                                           3        1               6               .358^\*\*^
  PDSS disturbed sleep domain   97.0%                                                                                                                           8        4               11              .707^\*\*^
  PDSS total score              98.3%                                                                                                                           15       9               23              .598^\*\*^

^\*\*^ *P* \< 0.01.

###### 

Prevalence, frequency, and correlation values for daytime sleep-related problems.

                       Prevalence   Frequency of score 0   Frequency of score 1   Frequency of score 2   Frequency of score 3   Frequency of score 4   Median   Percentile 25   Percentile 75   Correlation with MDS-UPDRS item 1.8
  -------------------- ------------ ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- -------- --------------- --------------- -------------------------------------
  MDS-UPDRS item 1.8   75.1%        115                    88                     224                    29                     5                      2        1               2               1.000
                                                                                                                                                                                                
  ESS item number 01   69.6%        140                    161                    109                    51                                            1        0               2               .423^\*\*^
  ESS item number 02   82.2%        82                     157                    150                    72                                            1        1               2               .446^\*\*^
  ESS item number 03   42.1%        267                    122                    45                     27                                            0        0               1               .373^\*\*^
  ESS item number 04   51.8%        222                    130                    79                     30                                            1        0               1               .330^\*\*^
  ESS item number 05   88.5%        53                     103                    114                    191                                           2        1               3               .293^\*\*^
  ESS item number 06   15.4%        390                    50                     20                     1                                             0        0               0               .249^\*\*^
  ESS item number 07   55.5%        205                    129                    76                     51                                            1        0               2               .278^\*\*^
  ESS item number 08   13.9%        397                    45                     17                     2                                             0        0               0               .254^\*\*^
                                                                                                                                                                                                
  ESS total score      95.3%                                                                                                                           7        4               10              .494^\*\*^

^\*\*^ *P* \< 0.01.
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